BridgeBio Pharma Inc (BBIO)

BridgeBio Pharma Inc (BBIO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $13.4B; returns 1 day +0.6%, 1 week +3.3%, 1 year +27.4%.

BridgeBio Pharma Inc. (BBIO) is a commercial-stage biopharmaceutical company primarily focused on discovering, developing, and delivering transformative medicines for genetic diseases and genetically-driven cancers. The company operates with a decentralized model, managing a diverse pipeline of programs ranging from early-stage research to advanced clinical trials.

Groups BBIO belongs to

• Biopharmaceutical
• Biotechnology
• Rare Diseases
• Healthcare
• Commercial Stage Biotech
• Cardiovascular Therapies
• Life Sciences
• Pharmaceuticals
• Clinical Stage Biotech
• Oncology
• Precision Medicine

BBIO financial model: income statement, cash flow and balance sheet